Last update :
29/10/2024
Anticancer drug   Epirubicin hydrochloride  
injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Anthracine Malaysia
Axirubicine Germany
Bendaepi Germany
Binarin Mexico
Bioepycina Poland
Crisabon Argentina
Cuatroepi Argentina
Ecclepia Romania
Elebicin Mexico
Ellence United States of America
Epi Cell Germany
Epidoxo Argentina, Chile, Venezuela
Epifil Ecuador
Epilem Colombia, Mexico
Epimedac Germany
Epirubicin Australia, Austria, Belgium, Denmark, Great Britain, Hungary, Iceland, New Zealand, Saudi Arabia, Sweden, Switzerland, Turkey
Epirubicina Argentina, Colombia, Ecuador, Mexico, Romania, Spain
Epirubicine Belgium, France, Switzerland
Farmarubicin Turkey
Farmorubicin Austria, Brazil, Denmark, Finland, Greece, Norway, Saudi Arabia, Sweden, Switzerland
Farmorubicin CSV Republic of South Africa
Farmorubicin PFS Croatia, Poland, Slovenia
Farmorubicin RD Brazil, Poland, russian, Switzerland
Farmorubicin RTU Netherlands
Farmorubicina Brazil, Italy, Portugal, Spain
Farmorubicine Belgium, France
Pharmorubicin Great Britain
References   injection   References : Epirubicin hydrochloride  
Type Publication
148 Journal Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I.
Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags.
Pharm Weekbl [Sci] 1992 ; 14: 365-369.
525 Journal De Vroe C, De Muynck C, Remon JP, Samsom M.
A study on the stability of three antineoplastic drugs and on their sorption by IV delivery systems and end-line filters.
Int J Pharm 1990 ; 65: 49-56.
683 Journal Walker SE, Lau DWC, DeAngelis C, Iazetta J, Coons C.
Epirubicin stability in syringes and glass vials and evaluation of chemical contamination.
Can J Hosp Pharm 1990 ; 43: 265-272.
686 Journal Wood MJ, Irwin WJ, Scott DK.
Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags.
J Clin Pharm Ther 1990 ; 15: 279-289.
887 Journal Pujol M, Munoz M, Prat J, Giona V, De Bolos J.
Stability study of epirubicin in NaCl 0.9% injection.
Ann Pharmacotherapy 1997 ; 31: 992-995.
1237 Journal Keusters L, Stolk LML, Umans R, Van Asten P.
Stability of solutions of doxorubicin and epirubicin in plastic minibags for intravesical use after storage at -20°C and thawing by microwave radiation.
Pharm Weekbl [Sci] 1986 ; 8: 194-197.
1265 Journal Wood MJ, Irwin WJ, Scott DK.
Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography.
J Clin Pharm Ther 1990 ; 15: 291-300.
1317 Journal Adams PS, Haines-Hutt RF, Bradford E, Palmer A, Rowland CG.
Pharmaceutical aspects of home infusion therapy for cancer patients.
Pharm J 1987 ; 238: 476-478.
1662 Journal Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1823 Journal Sewell GJ, Rigby-Jones AE, Priston MJ.
Stability of intravesical epirubicin infusion: a sequential temperature study.
J Clin Pharm Ther 2003 ; 28: 349-353.
1897 Journal Sautou-Miranda V, Brigas F, Thibault M, Chopineau J.
Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage.
EJHP 2001 ; 7, 3: 108-115.
1955 Journal Trissel LA, Zhang Y.
Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration.
Ann Pharmacotherapy 2005 ; 39: 280-283.
2168 Journal Ozdemir FA, Anilanmert B, Pekin M.
Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution.
Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534.
2257 Manufacturer Stability of epirubicin "Ebewe" infusion solutions.
Ebewe Pharma 2007
3473 Journal Bennis Y, Savry A, Correard F, Montana M, Sauzet C, Gauthier-Villano L, Pisano P, Pourroy B.
Stability of a highly concentrated solution of epirubicin for conventional transcatheter arterial chemoembolization.
Int J Pharm 2015 ; 495, 2: 956-962.
3474 Manufacturer Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3632 Manufacturer Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics
Hospira 2017
3670 Journal Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3708 Poster Sarakbi I, Thiesen J, Krämer I.
Compatibility of epirubicin-loaded DC Beads with different contrast media.
ECOP 2 Krakow 2014
3918 Journal Sarakbi I, Krämer I.
Compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media.
J Oncol Pharm Practice 2016 ; 22: 749-756.
4352 Journal Li J, Yao C, Xu Y, Ping P, Yin H, Sun Y.
In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag.
J Clin Pharm Ther 2019 ; 44: 875-882.

  Mentions Légales